Collectively, these results demonstrate a requirement for NPY1R in PC metastasis and warrant further assessment of the NPY/NPY1R signaling axis as a cotarget in conjunction with current and contemporary standard-of-care therapies in PC (5, 6). This evidence concerns the gene NPY1R and pachyonychia congenita.